These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 25123886)
1. [Financing for rare or orphan diseases: a thing to do]. Hernández-Vásquez A; Rubilar-González J; Pisfil-Benites N Rev Peru Med Exp Salud Publica; 2014 Apr; 31(2):393. PubMed ID: 25123886 [No Abstract] [Full Text] [Related]
2. [Going from research to development: which support and financing tools?]. Roques S Presse Med; 2012 May; 41 Suppl 1():S43-5. PubMed ID: 22465719 [No Abstract] [Full Text] [Related]
3. Drug companies' patient-assistance programs--helping patients or profits? Howard DH N Engl J Med; 2014 Jul; 371(2):97-9. PubMed ID: 25006717 [No Abstract] [Full Text] [Related]
4. There is such a thing as a free lunch. Social policy in the Clinton health plan. McKenzie N; Levin A Health PAC Bull; 1993; 23(3):22-5. PubMed ID: 10131489 [No Abstract] [Full Text] [Related]
5. Lucrative niches: how drugs for rare diseases became lifeline for companies. Anand G Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531 [No Abstract] [Full Text] [Related]
6. [Rare diseases in Lebanon: diagnostic difficulties and therapy]. Mansour H Arch Pediatr; 2015 May; 22(5 Suppl 1):1-2. PubMed ID: 26112493 [No Abstract] [Full Text] [Related]
7. Mexico and the tobacco industry: doing the wrong thing for the right reason? Samet J; Wipfli H; Perez-Padilla R; Yach D BMJ; 2006 Feb; 332(7537):353-4. PubMed ID: 16470060 [TBL] [Abstract][Full Text] [Related]
9. [Rare diseases in pulmonary medicine and its challenges]. Wencker M; Teschler H; Vogelmeier C; Koczulla R Pneumologie; 2012 Jul; 66(7):437-41. PubMed ID: 22692970 [TBL] [Abstract][Full Text] [Related]
10. Health care financing and insurance. Options for design. Paolucci F Dev Health Econ Public Policy; 2011; 10():1-114. PubMed ID: 21247006 [No Abstract] [Full Text] [Related]
11. [Round table 4. Speeding new therapeutic approaches for rare diseases: do we need new economical models or financial tools?]. Med Sci (Paris); 2014 Apr; 30 Spe(1):47-53. PubMed ID: 24755179 [No Abstract] [Full Text] [Related]
13. Too much of a good thing? Insurers are stashing massive cash reserves, but critics wonder how much is enough and question how the money is being used. Benko LB Mod Healthc; 2002 Sep; 32(36):30-2. PubMed ID: 12298324 [No Abstract] [Full Text] [Related]
14. [Rare diseases are not orphan any longer]. Cordier JF Rev Prat; 2012 Jan; 62(1):3. PubMed ID: 22335057 [No Abstract] [Full Text] [Related]
15. [Financing rare or orphan diseases]. Oyola-García A; Lituma-Aguirre D; Honorio-Morales H; Rev Peru Med Exp Salud Publica; 2014; 31(4):808-9. PubMed ID: 25597742 [No Abstract] [Full Text] [Related]
16. [Financing of health insurance]. MERELLO AL Sem Med; 1960 Nov; 117():1750-60. PubMed ID: 13769582 [No Abstract] [Full Text] [Related]
17. Adverse selection in the health care financing system. Archer RL Bests Rev Life Health Insur Ed; 1978 Oct; 79(6):10, 12, 87. PubMed ID: 10238975 [No Abstract] [Full Text] [Related]
18. The cost conundrum: financing the business of health care insurance. Kelly A J Health Care Finance; 2013; 39(4):15-27. PubMed ID: 24003758 [TBL] [Abstract][Full Text] [Related]
19. Health insurance in China and India: segmented roles for public and private financing. Bhattacharjya AS; Sapra PK Health Aff (Millwood); 2008; 27(4):1005-15. PubMed ID: 18607034 [TBL] [Abstract][Full Text] [Related]
20. Child Support Enforcement program; medical support. Final regulation. Administration for Children and Families, Office of Child Support Enforcement (OCSE) Fed Regist; 2008 Jul; 73(140):42415-42. PubMed ID: 18956489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]